# Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

> **NCT05489848** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 294 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **RADIATION:** EBRT
- **RADIATION:** VBT

## Key facts

- **NCT ID:** NCT05489848
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-08-20
- **Primary completion:** 2028-08-20
- **Final completion:** 2030-08-20
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489848, "Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05489848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*